Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines.


Journal

Therapeutic innovation & regulatory science
ISSN: 2168-4804
Titre abrégé: Ther Innov Regul Sci
Pays: Switzerland
ID NLM: 101597411

Informations de publication

Date de publication:
03 2020
Historique:
received: 22 10 2018
accepted: 26 02 2019
entrez: 20 2 2020
pubmed: 20 2 2020
medline: 3 6 2021
Statut: ppublish

Résumé

This paper provides examples of defining estimands in real-world scenarios following ICH E9(R1) guidelines. Detailed discussions on choosing the estimands and estimators can be found in our companion papers. Three scenarios of increasing complexity are illustrated. The first example is a proof-of-concept trial in major depressive disorder where the estimand is chosen to support the sponsor decision on whether to continue development. The second and third examples are confirmatory trials in severe asthma and rheumatoid arthritis respectively. We discuss the intercurrent events expected during each trial and how they can be handled so as to be consistent with the study objectives. The estimands discussed in these examples are not the only acceptable choices for their respective scenarios. The intent is to illustrate the key concepts rather than focus on specific choices. Emphasis is placed on following a study development process where estimands link the study objectives with data collection and analysis in a coherent manner, thereby avoiding disconnect between objectives, estimands, and analyses.

Identifiants

pubmed: 32072586
doi: 10.1007/s43441-019-00065-7
pii: 10.1007/s43441-019-00065-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

370-384

Auteurs

Bohdana Ratitch (B)

Eli Lilly, Montreal, Quebec, Canada.

Niti Goel (N)

Kezar Life Sciences, South San Francisco, CA, USA.
Department of Medicine, Duke University School of Medicine, Durham, NC, USA.

Craig Mallinckrodt (C)

Biogen, Cambridge, MA, USA.

James Bell (J)

Elderbrook Solutions GmbH, High Wycombe, United Kingdom.

Jonathan W Bartlett (JW)

Department of Mathematical Sciences, University of Bath, Bath, United Kingdom.

Geert Molenberghs (G)

I-BioStat, Universiteit Hasselt and KU Leuven, Hasselt, Belgium.

Pritibha Singh (P)

Novartis, Basel, Switzerland.

Ilya Lipkovich (I)

Eli Lilly, Indianapolis, IN, USA.

Michael O'Kelly (M)

IQVIA, Estuary House, East Point Business Park, Dublin 3, Ireland. Michael.OKelly@iqvia.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH